The film will be followed by a post-screening conversation with Phil Sharp, Bill Haney, and Clint Gartin and a reception with food an drinks.

Phillip A. Sharp, PhD – Phillip A. Sharp, an Institute Professor emeritus at MIT, is a member of the Department of Biology and the Koch Institute for Integrative Cancer Research. His work studying the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing earned Sharp the 1993 Nobel Prize in Physiology for Medicine. Sharp is past President of AAAS, serves on the boards of directors of the Broad Institute, Stand Up 2 Cancer, and the Gairdner Foundation. He is a co-founder of Biogen and of Alnylam Pharmaceuticals and serves on the Scientific Advisory Boards of F-Prime Capital, Alnylam Pharmaceuticals, Danahers, Dewpoint Therapeutics, and Skyhawk Therapeutics, He is also advisor to Longwood and Polaris Venture Funds.

Clint Gartin – Clint Gartin is a Senior Advisor at Morgan Stanley and was the Chairman of Investment Banking at Morgan Stanley for eight years. He was previously the head of Morgan Stanley’s Healthcare Investment Banking Group for seventeen years. He has also served as the Chief Operating Officer of Morgan Stanley’s Investment Banking Division and as the head of its Global Industries Group. Mr. Gartin has been involved in over $1.6 trillion of merger and acquisition transactions and has been involved in over 150 capital raising events. His clients include some of the largest companies in the world. Mr. Gartin received a degree in accounting from the University of Connecticut where he was a University Scholar and graduated summa cum laude. He joined Morgan Stanley in 1981 after receiving an MBA from Harvard Business School.

Bill Haney – Bill Haney is a filmmaker, inventor, and entrepreneur. His most recent film projects include Cracking the Code: Phil Sharp and the Biotech Revolution, and Jim Allison: Breakthrough. He has started more than a dozen companies and is currently the Co-founder and CEO of Dragonfly Therapeutics, a clinical stage biotech focused on novel NK-cell based immune engagers, and Co-founder & Chairman of Skyhawk Therapeutics, a clinical stage biotech focused on small molecule RNA splicing modifiers. Bill is a graduate of Harvard College and served as a Fellow of Harvard's Kennedy School.